OncoArendi Therapeutics has opened a modern R&D laboratory

The OncoArendi Therapeutics SA team officially opened a new research and development laboratory in od. The laboratory space located in a modern building in the city center will enable the expansion and intensification of the Company's research work in the field of medical chemistry and molecular biology conducting screening tests, crucial for the effective implementation of the OncoArendi further development strategy.

500 m2 has been allocated for the new laboratory space, which is more than twice as much as the od team of OncoArendi scientists had at their disposal so far. The new laboratories will be equipped with the highest quality equipment, enabling work at the world level, also in the field of molecular biology, which until now was only possible at the Warsaw headquarters of OncoArendi.

The new laboratory will conduct research ranging from the analysis of the structure of potential therapeutic targets to the synthesis of advanced molecules, potential drugs (drug candidates),which will then be studied in a cycle of in-vitro tests before moving to the next phases of their preclinical and clinical development.

'The medical chemistry department is the unit in the structure of our company in which the design, synthesis and optimization of hundreds or even thousands of chemical compounds takes place, from which one molecule (called a clinical candidate) is selected for further development. Thanks to the fact that in the new laboratory we will also study the biological activity of the compounds synthesized by us (both in terms of their expected activity towards the assumed molecular targets and their potential side effects), we will be able to significantly reduce the time necessary to reach this stage of the process of discovering a new drug' - says Jacek Olczak, Director of Medical Chemistry and co-founder of OncoArendi Therapeutics SA.

'The new lab opens up a space where we will develop breakthrough drugs. The provision of modern research infrastructures and the creation of the best possible working conditions are necessary to achieve this goal. The company is growing rapidly and is entering new strategic research areas, such as the RNA-modifying drug discovery platform. The highest standard of laboratory space and the combination of the unique competencies of our team of scientists, both in medical chemistry and biology, are extremely important for the development of our programs. This applies to both programs in which our molecules interact with proteins and those that target RNA. That is why the new laboratory in od is a great opportunity for us to expand the scope of research and the number of projects being developed with a huge market potential.' - comments Marcin Szumowski - President of the Management Board of OncoArendi.

Contact:

OncoArendi Therapeutics SA

Pisudskiego 141, 92-318

Mobile: [phone]

E: [e-mail]

(C) 2021 Electronic News Publishing, source ENP Newswire